Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
China is yet to approve a RSV vaccine, unlike the U.S. which has given the green light to shots from GSK, Moderna and Pfizer, but multiple candidates have reached the clinic ahead of Ab&B.
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced.The vaccine, branded as ...
Hosted on MSN1mon
Why Pfizer sold its $3 billion stake in HaleonHaleon, known for brands such as Sensodyne, Panadol, and Advil, was created through the merger of GSK and Pfizer’s consumer healthcare businesses in 2019 and spun off as a standalone entity in 2022.
It wants to get ahead of competitors such as BMS, Merck, Pfizer ... The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new joint ...
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...
To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on ...
Hosted on MSN11mon
Pfizer to Raise Around $3.5 Billion From Haleon Shares SalePfizer is raising around $3.5 billion from the sale of part of its stake in consumer-healthcare business Haleon. The pharmaceutical giant is reducing its shareholding in Haleon to 22.6% from 32% ...
The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British ...
Both Pfizer and Seagen have been asked to supply “additional information and documentary materials” in relation to the $229-per-share merger ... worth up to $14.6bn. GSK confirms that it ...
Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly in the last three months of 2024, compared the same period one year before. In a earnings report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results